Molecular Diagostics Market By ROCHE DIAGNOSTICS, ILLUMINA, HOLOGIC CORPORATION, AGILENT TECHNOLOGIES/DAKO, QIAGEN, MYRIAD GENETICS, ABBOTT LABORATORIES, CEPHEID , GENOMIC HEALTH, GRIFOLS SA

The global molecular diagnostics market has been estimated at around USD 7000 million in 2017. The market is expected to register a CAGR of approximately 9% during the forecast period, 2018 to 2023. North America accounted for the largest market, followed by Europe, in the molecular diagnostics market. Asia-Pacific was estimated to register approximately 15% CAGR through the forecast period, 2018-2023.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16679
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Point-of-Care Diagnostics Demand
Point-of-care testing is an emerging field in diagnostics. This generalized term encompasses tests that are portable and provide rapid results. The genetic material of an infectious agent used for detection is one of the fastest-growing point-of-care test types. Near-patient and POC tests, currently, exist for a number of pathogens, such as influenza, tuberculosis (TB), and other respiratory viruses, such as Chlamydia, gonorrhea, and group A Streptococcus (GAS). These include antigen tests (most commonly lateral-flow immunochromatographic membrane-based assays and nucleic acid tests. The POC tests are widely accepted because many tests are portable, fast, fairly simple to use, and inexpensive. Along with other factors, such as large outbreaks of bacterial and viral epidemics in the world, the rapidly evolving technology is driving the molecular diagnostics market.

Key Developments in the Market
• December 2017: Saudi Arabia announced the exemption of certain medications and medical equipment from the 5% VAT, which is scheduled to be implemented from January of 2018. Saudi Arabia is imposing VAT in coordination with other governments in the Gulf Cooperation Council as they seek new sources of revenue in a bid to close budget deficits caused by low oil prices.
• October 2017: Abbott completed acquisition of Alere Inc. It is a global manufacturer of rapid point-of-care diagnostic tests.
• July 2017: Agilent Technologies had acquired molecular and sample barcoding patent portfolios of Population Genetics Technologies.

Major Players:
ROCHE DIAGNOSTICS, ILLUMINA INC., HOLOGIC CORPORATION, AGILENT TECHNOLOGIES/DAKO, QIAGEN, MYRIAD GENETICS, ABBOTT LABORATORIES, CEPHEID INC., GENOMIC HEALTH INC., GRIFOLS SA amongst others.

Request Discount on this report @ https://marketprognosis.com/discount-request/16679
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Budget Limit
The end users of the market include, academic and research laboratories Fluctuation in the R&D budget can adversely affect the market growth; R&D funding fluctuates by the change in spending priorities and institutional budget. There is significant uncertainty concerning government and academic research funding worldwide, as governments in the United States and European countries, in particular, focus on reducing fiscal deficits, while confronting uncertain economic growth. Funding for life science research in some emerging countries is declining. Government funding for R&D depends on the political process, which is inherently fluid and unpredictable. Focus on programs, like defense or general efforts to minimize budget deficits can be a high priority of the government. Hence, factors, like limited budgets for R&D and economic slowdown, are restraining the growth of the market, along with other factors, such as the need for high-complexity testing centers, which are also limiting the growth of the market.

North America to Dominate the Market Growth
North America accounted for the largest market, accounting for around 44% of the global market share. The availability of robust healthcare infrastructure in North America has propelled the demand for molecular diagnostics. Along with North America, Europe is also the leading region in the global molecular diagnostics market. Asia-Pacific is fastest-growing region for molecular diagnostics and portrays huge potential for growth in the future, due to increasing government initiatives, corporate investment to standardize biopharmaceutical and healthcare industries in this region. and are projected as the fastest growing markets during the forecast period.

Enquiry Before Buying@ https://marketprognosis.com/enquiry/16679
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.